Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases

A multicenter Phase 3 imaging trial plans to enroll approximately 280 patients with brain metastases. The study is designed to demonstrate sensitivity and specificity above prespecified performance thresholds; no trial results are reported.